Investment Committee Summary
| Rating | HOLD |
| Internal 5-tier | HOLD |
| Classification · conviction | mature cash generator · medium |
| Evidence | 8/8 load-bearing inputs sourced |
| Triangulated fair value | $81.53 (-17% vs spot · triangulated FV) |
| 12-mo scenario PWEV | $95.16 (-3% vs spot · 12m PWEV) |
| Next catalyst | 2026-10-15 — Bolt-on acquisition close / capital-deployment update |
| Primary thesis-break | organic revenue growth (YoY) < 0.015 (2 consecutive prints) |
Decision detail — rating tables & Research OS strip
Rating: HOLD
Internal 5-tier: HOLD · mature cash generator · analyst conviction: medium
| Metric | Value |
|---|---|
| Current Price | $98.11 |
| Triangulated Fair Value | $81.53 (-17% vs spot · triangulated FV) |
| 12-mo Scenario PWEV | $95.16 (-3% vs spot · 12m PWEV) |
| Forward P/E | 26.0x |
| Market Cap | $23B |
| 52-Week Range | $81.33–$106 (intraday high and low over the trailing 52 weeks of the stock's own daily bars) |
EPS basis for the forward P/E and all scenario multiples: consensus forward EPS (broker-adjusted, non-GAAP).
Methodology: Valuation triangulated across four weighted anchors — an intrinsic DCF, a scenario-weighted PWEV, a Monte Carlo median (Student-t + regime switching) and a peer P/E re-rate. Anchors are blended at fixed declared weights, each counted separately; the Monte Carlo, the scenario PWEV and the DCF's exit-multiple terminal all rest on the same base multiple, so where they agree it is partly by construction — not independent corroboration. Figures reconciled to Alpha Vantage 2026-10-09. Each chart below sits with the part of the thesis it evidences.
General research, published identically to every reader. Not personal financial advice. Figures as of the analysis date; verify before acting.
Decision Support — Research OS jump to detail ↓
| Research conviction | Exp. return (1y) | Rules stance | Next catalyst |
|---|---|---|---|
| 59.1/100 (54th pct) | -2% 1yr expected | Hold | 3d — Bolt-on acquisition close / capital-deployment update |
Full breakdown — conviction components, probability-return distribution, decision rules, factor & portfolio interaction and the catalyst timeline — in the Decision Support sections below. Model output for research; not personal financial advice.
📎 Download the full model (Excel) — DCF line items, scenarios, sensitivity, assumptions, and extended fundamentals.
Recommendation: HOLD
Balanced: triangulated fair value $81.53 (-17% vs spot); the outcome hinges on P/E Multiple. The debate is P/E Multiple — fundamentally a multiple/regime call.
Investment Thesis
At $98.11 (12 October 2026) Church & Dwight trades on roughly 26x forward earnings against a household-staples peer median well below that. The market is paying a premium for low-single-digit pricing-led organic growth and an operating margin of 17% (reported GAAP, TTM to Jun 2026), and treating both as durable. The engine is less generous. The cash-flow anchor reads materially lower, peer-multiple triangulation lower still, and the simulation median sits beneath the current price; together they pull the blend to $81.53, a gap of -17% that leaves the shares trading rich to the anchor set. Probability-weighted value of $95.16 and a twelve-month target of $96.60 are held up almost entirely by the base case and by the weight sitting in the two upside scenarios, where the premium is in the multiple rather than in the earnings. HOLD follows, because the gap between the weighted target and the current price is inside noise while the gap to the anchor set is not, and net debt of ~$1.9B is comfortably serviced either way. The most damaging risk is structural private-label substitution: that scenario's target sits below the 52-week low, and no defensive multiple survives it.
Narrative drafted 2026-08-16 by claude-opus-5 under supervision; reviewed by Marinus 2026-08-16.
The dashboard below is the whole argument on one page: spot ($98.11) against each valuation anchor, the scenario tree, technicals and the options-implied move.
Anti-Thesis (The Real Bear Case)
The bear mechanism is substitution, not recession. The portfolio is concentrated in mid-priced household staples — laundry, litter, personal care — where private label is closest in quality and the retailer controls the shelf. If trade-down persists beyond one cycle, retailers reallocate facings to own-brand, promotional intensity rises, and pricing power inverts: volume has to be bought back with discount. Revenue declines while the operating margin compresses well below 17% (reported GAAP, TTM to Jun 2026) as fixed costs deleverage and the value positioning of the core Arm & Hammer franchise caps price recovery. Reduced earnings power then meets a multiple far beneath 26x — the two compress together rather than in sequence. The vitamins business has already shown how quickly one of this company's categories can impair, and the current multiple concedes none of that fragility. That is the path on which the structural target sits below the 52-week low.
Key Debate
P/E Multiple explains 55% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.
What the Market Is Pricing In
At the current price, the market pays 26.0× consensus forward EPS, vs the house DCF terminal 22.0×, and a peer median 15.1×. The house DCF sits 22% below spot, so the market is pricing in more than the house case — roughly 2.2pp of revenue CAGR.
Variant perception: the house view is below-consensus, and the thesis is primarily growth-driven.
| Metric | Consensus | House | Importance |
|---|---|---|---|
| Revenue | 6.2 | 6.5 | High |
| EPS | 3.8 | 3.8 | Medium |
| Target price | 104.8 | 96.6 | Medium |
Scenario Analysis
The scenario tree spans a structural 'Structural — Private-Label / Brand Erosion' downside ($44.50) to a 'Bull — Defensive Re-Rate' bull case ($156); the probability-weighted blend (PWEV $95.16) is -3% versus spot.
| Scenario | Probability | Target | Return vs spot |
|---|---|---|---|
| Structural — Private-Label / Brand Erosion | 20% | $44.50 | -55% |
| Consumer / Input Recession | 18% | $80.50 | -18% |
| Base — Pricing-Led Organic Growth | 34% | $103 | +5% |
| Growth — Premium Innovation + EM | 20% | $129 | +31% |
| Bull — Defensive Re-Rate | 8% | $156 | +59% |
| Probability-Weighted (PWEV, after SBC dilution) | — | $95.16 | -3% |
SBC charge: scenario targets are gross per-share prices; the PWEV is reduced by one year of stock-based-compensation dilution (1.5% of shares, on SBC ≈ 1% of revenue), trimming the gross PWEV of $96.58 to $95.16 (-1.5%). SBC is charged once, as dilution — never also deducted from FCF.
Scenario rationale — the driver path behind every target:
- Structural — Private-Label / Brand Erosion (20%, $44.50). Structural impairment — private-label / brand erosion: earnings AND the multiple compress together. Target sits below the 52-week low by construction.
- Consumer / Input Recession (18%, $80.50). Cyclical downturn — branded HPC pricing power + organic volume + input costs (beauty: China/travel-retail) weakens for 1–2 years before normalising.
- Base — Pricing-Led Organic Growth (34%, $103). Mid-cycle — normalised branded HPC pricing power + organic volume + input costs (beauty: China/travel-retail); disciplined capital allocation; steady returns.
- Growth — Premium Innovation + EM (20%, $129). Upside — premium innovation + emerging markets lifts earnings above mid-cycle; the multiple expands modestly.
- Bull — Defensive Re-Rate (8%, $156). Upside tail — sustained tight conditions or a structural re-rate on premium innovation + emerging markets.
Valuation Triangulation
Four weighted anchors — an intrinsic dcf, a scenario-weighted pwev, a monte carlo median (student-t + regime switching) and a peer p/e re-rate — read them with their basis in mind. The Monte Carlo, the scenario PWEV, any DCF's exit-multiple terminal and any peer re-rate key off a market multiple, so they are not independent; only a DCF's explicit-period cash flows are multiple-free, and its terminal usually carries most of its value. The discipline is to read the spread, not to treat four numbers as four independent votes.
| Method | Basis | Fair Value | vs Spot | Weight in this name's blend |
|---|---|---|---|---|
| Monte Carlo median (Student-t + regime) | multiple | $87.93 | -10% | 18% (declared 15%) |
| Peer P/E re-rate | multiple | $57.06 | -42% | 12% (declared 10%) |
| Peer EV/Revenue re-rate | multiple | $58.18 | -41% | 0% — cross-check only |
| Scenario PWEV | multiple | $95.16 | -3% | 29% (declared 25%) |
| DCF (5-year + exit-multiple terminal) | cash flow + terminal × | $76.05 | -22% | 41% (declared 35%) |
| Triangulated (weighted) | — | $81.53 | -17% | 100% |
The house blend DECLARES five anchor weights — DCF 35%, scenario PWEV 25%, Monte Carlo 15%, sum-of-parts 15%, peer re-rate 10%. For this name sum-of-parts is not computed, so 15% of the declared weight is redistributed across the anchors that exist — which is why the weights above differ from the declared ones. The fair value is unaffected by this disclosure; the blend has always worked this way. The company-lever row in the Sensitivity section is an illustrative EBIT × multiple value, not a sum-of-parts anchor.
Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.
Rating vs blend — the key debate. The rating tracks the multiple-discipline fair value (Monte Carlo $87.93 + scenario PWEV $95.16, ≈ spot); the weighted blend $81.53 (-17%) sits below it because the exit-multiple DCF ($76.05) is materially more conservative than the market multiple. Whether the current multiple is justified is the central question for this name — and the principal downside risk to the rating.
Monte Carlo — the outcome distribution
10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $87.93 and 40% of paths finish above spot. The variance decomposition shows the p/e multiple is the dominant swing factor (55% of variance). Value is a multiple bet: fundamentals move the answer far less than the rating does.
DCF — explicit-period cash flows with an exit-multiple terminal
A 5-year cash-flow path discounted at a WACC of 7.5%, plus a terminal value of final-year FCF × 22.0x — a terminal multiple equal to 0.85 × the base multiple that the Monte Carlo and the scenario tree also use → $76.05. The terminal value is 80% of enterprise value, so this anchor moves with the multiple assumption. The heaviest anchor in this blend (41%); because its terminal is a market multiple, it is not independent of the multiple-driven anchors.
Peer benchmarking — relative value
Against its 3 peers in the same GICS sub-industry, re-rating to their median forward multiple (P/E 15.1x) implies $57.06. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 12% so market sentiment does not set the fair value.
Across all anchors the spread is 50% of the median — wide (genuine disagreement — the blend carries low valuation confidence).
Sensitivity
DCF/share — WACC × terminal multiple
| WACC \ Term× | 15.4x | 18.7x | 22.0x | 25.3x | 28.6x |
|---|---|---|---|---|---|
| 5.5% | $61.40 | $72.51 | $83.63 | $94.75 | $106 |
| 6.5% | $58.53 | $69.13 | $79.74 | $90.34 | $101 |
| 7.5% | $55.81 | $65.93 | $76.05 | $86.17 | $96.29 |
| 8.5% | $53.23 | $62.89 | $72.56 | $82.22 | $91.88 |
| 9.5% | $50.79 | $60.02 | $69.25 | $78.47 | $87.70 |
DCF/share — revenue CAGR Δ × model op-margin Δ (Δ applied to the DCF's house margin path)
| CAGRΔ \ MgnΔ | -3.0pp | -1.5pp | +0.0pp | +1.5pp | +3.0pp |
|---|---|---|---|---|---|
| -3.0pp | $52.87 | $58.95 | $65.04 | $71.12 | $77.20 |
| -1.5pp | $57.37 | $63.88 | $70.39 | $76.90 | $83.41 |
| +0.0pp | $62.13 | $69.09 | $76.05 | $83.01 | $89.97 |
| +1.5pp | $67.16 | $74.60 | $82.03 | $89.47 | $96.90 |
| +3.0pp | $72.48 | $80.42 | $88.35 | $96.29 | $104 |
Tornado — DCF/share swing by driver (widest first)
| Driver | Low | High | Swing |
|---|---|---|---|
| Model op margin ±3pp | $62.00 | $90.00 | $28.00 |
| Revenue CAGR ±3pp | $65.00 | $88.00 | $23.00 |
| Terminal × ±15% | $66.00 | $86.00 | $20.00 |
| WACC ±1pp | $73.00 | $80.00 | $7.00 |
| Capex intensity ±15% | $73.00 | $79.00 | $5.00 |
Company lever — value at the base multiple vs Household & Personal Care multiple (base 26.0x)
| Multiple | 18.2x | 22.1x | 26.0x | 29.9x | 33.8x |
|---|---|---|---|---|---|
| Value at the base multiple (EBIT × multiple; illustrative, not a blend anchor) | $77.00 | $95.00 | $113 | $131 | $150 |
Illustrative: segment EBIT × multiple, plus net cash, over basic shares — it does not enter the triangulated fair value.
Peer Quality & Weighting
| Peer | Fwd P/E | Growth | Op margin | Quality | Weight cap |
|---|---|---|---|---|---|
| CL | 23.6× | 4% | 21% | direct | 100% |
| KMB | 14.2× | 4% | 20% | segment | 50% |
| CLX | 15.1× | 4% | 17% | segment | 50% |
Quality-weighted forward P/E: 19.1× (simple median 15.1×). Direct peers count 100%, segment 50%, broad 25%.
Historical-range cross-check: 52-week range $81.33–$106, centre $92.90 (-5% vs spot); spot sits at the 68th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.
Risk / Reward & Margin of Safety
| Metric | Value |
|---|---|
| Upside to triangulated FV (FV ÷ price − 1) | $81.53 (-17% vs spot · triangulated FV) |
| Downside to lowest scenario (Structural — Private-Label / Brand Erosion) | $44.50 (-55% vs spot · bear scenario) |
| Reward-to-risk ratio | withheld — the triangulated FV is at or below spot, so there is no reward leg to divide by the risk leg |
| Discount to fair value (1 − price ÷ FV) | -20% |
| P(price > spot) — Monte Carlo | 40% |
That ratio is (triangulated FV ÷ price − 1) ÷ (1 − 'Structural — Private-Label / Brand Erosion' target ÷ price). 'Structural — Private-Label / Brand Erosion' ($44.50, probability 20%) is the lowest-target scenario in the tree, taken gross of SBC dilution. With a leg missing the ratio is withheld rather than computed from a magnitude. Bull case (Bull — Defensive Re-Rate): $156.
Company Overview & Business Model
Church & Dwight Company Inc — CONSUMER DEFENSIVE · HOUSEHOLD & PERSONAL PRODUCTS. Church & Dwight Co., Inc., is a major American manufacturer of household products that is headquartered in Ewing, New Jersey.
Company description as supplied by Alpha Vantage; not checked against the company's filings.
How it makes money.
| Segment | Rev mix | Growth | Model op margin† | Key driver |
|---|---|---|---|---|
| Household & Personal Care | 100% | +4% | 18% | branded HPC pricing power + organic volume + input costs (beauty: China/travel-retail) |
† Model margin = gross margin − the opex ratio calibrated so the Monte Carlo median EPS meets the EPS target; it is not a reported operating margin.
Reported operating margin (GAAP): 17.4% for the fiscal year ended 2025-12-31; 17.5% TTM to 2026-06-30 (Alpha Vantage INCOME_STATEMENT).
Edge. Narrow moat — A narrow moat built on a handful of #1/#2 category brands (ARM & HAMMER, OxiClean, vitamins) plus a value-tier hedge justifies a modest premium to the staples median, but not the ~25x forward multiple embedded today; if private label keeps taking mid-tier share (the falsifiable test), the terminal multiple should compress toward the ~16x household-staples median rather than hold near 20x.
Revenue-Segment Breakdown
The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)
| Segment | Revenue | Mix | Growth | Model op margin† | Model EBIT | Multiple | Capex % | Tag |
|---|---|---|---|---|---|---|---|---|
| Household & Personal Care | $6.2B | 100% | 4% | 18% | $1.1B | 26.0x | 3% | ESTIMATE |
| † Model EBIT = revenue × the model margin, i.e. gross margin less the opex ratio the calibration solved for to meet the EPS target — not the company's reported operating income. |
For comparison, the company's reported GAAP operating margin was 17.4% for the fiscal year ended 2025-12-31; 17.5% TTM to 2026-06-30 (Alpha Vantage INCOME_STATEMENT).
Named Exposures
Demand & pricing cycle (FACT/ESTIMATE)
| Dimension | Assessment |
|---|---|
| driver | branded HPC pricing power + organic volume + input costs (beauty: China/travel-retail) |
| net_debt_or_cash_b | -1.87 |
Capital intensity & shareholder returns (ESTIMATE)
| Dimension | Assessment |
|---|---|
| capex_pct_revenue | 0.03 |
| div_yield | 0.0121 |
Structural risk vs optionality (INFERENCE)
| Dimension | Assessment |
|---|---|
| downside | private-label / brand erosion |
| upside | premium innovation + emerging markets |
Balance Sheet & Liquidity
| Metric | Value |
|---|---|
| Net debt | $1.8B — modestly levered |
| Net debt / EBITDA | 1.33x |
| Interest coverage (EBIT / interest) | 11.1x |
| Current ratio | 1.07x |
| Cash & ST investments | $0.4B |
Balance-sheet data as of 2025-12-31 (Alpha Vantage).
Capital Allocation
| Metric | Value |
|---|---|
| Free cash flow | $1.1B |
| Buybacks / dividends | $0.9B / $0.3B |
| Total shareholder yield | 5.1% |
| Payout as % of FCF | 108.6% |
| Reinvestment (capex / OCF) | 10.0% |
| SBC as % of FCF | 5.3% |
| Allocation stance | returning more than FCF (balance-sheet funded) |
Free-Cash-Flow Quality
| Metric | Value |
|---|---|
| FCF margin | 17.6% |
| FCF conversion (FCF / net income) | 148.3% |
| FCF yield | 4.7% |
| Capex intensity (capex / revenue) | 2.0% |
| FCF − SBC (diagnostic) | $1.0B |
| Capex split (maint / growth) | 70% / 30% — Capital-light HPC manufacturer; capex ~2-3% of revenue is mostly maintenance and automation, with a growth slice for capacity behind newer brands and vitamins |
Accounting quality: SBC 1% of revenue; cash conversion (OCF/NI) 165% — cash-backed.
Competitive Moat
Moat sources:
- FACT: portfolio of 'power brands' with roughly 40% of profit from a concentrated set of #1/#2 share categories (10-K category disclosure)
- FACT: dual value/premium positioning (ARM & HAMMER value tier) that captures trade-down as well as trade-up
- INFERENCE: shelf-space and retailer-relationship scale at Walmart/Amazon, though below CL/PG in bargaining power
- ABSENCE: no structural switching costs or network effects; brand equity is the sole moat source and is erodible by private label
Earnings-Call Disconfirmation & Sentiment
Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.
Management vs analyst tone (2026Q2): management +0.69 vs analyst floor +0.01 → delta +0.68 (n=34 mgmt / 25 Q&A; 96th pctile across the S&P book, z +1.7).
Flag: ELEVATED — management unusually upbeat vs the analyst floor relative to peers (disconfirmation watch).
| Quarter | Mgmt | Analyst | Delta |
|---|---|---|---|
| 2026Q2 | +0.69 | +0.01 | +0.68 |
| 2026Q1 | +0.53 | +0.00 | +0.53 |
| 2025Q4 | +0.75 | — | — |
| 2025Q3 | +0.39 | +0.23 | +0.16 |
News (last 365d, 1262 articles): avg ticker sentiment +0.14 (bullish 14% / bearish 2%)
Consensus & Market Expectations
| Reference | Value |
|---|---|
| Street target (mean) | $105 (+7% vs spot · street) |
| House target | $96.60 (-7.9% vs street) |
| Sell-side coverage | 21 analysts (SB 2 / B 8 / H 9 / S 0 / SS 2; net score 0.19) |
| Consensus FY EPS | $3.77 (reference only — house values on EV/EBITDA) |
| Consensus FY revenue | $6.2B; house above (+4.2%) |
_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.
Catalyst Calendar
- 2026-10-15 (~6d) — Bolt-on acquisition close / capital-deployment update (authored)
- 2026-10-30 (~21d) — Quarterly earnings — est. EPS $0.90 (AV EARNINGS_CALENDAR)
- 2027-01-28 (~111d) — FY2026 results + FY2027 organic-growth and margin guidance (authored)
- 2027-02-15 (~129d) — Long-range algorithm / investor update (authored)
Forecast Track Record
- EPS surprise: beat 75% of the last 8 quarters; average surprise +5.2%.
Catalyst Timeline
6 catalysts in the next 90 days (of 15 tracked). Importance 1–3; confidence 0–1.
| When | Catalyst | Type | Importance | Confidence |
|---|---|---|---|---|
| 2026-10-14 (in 2d) | September CPI | macro | ●● | 0.8 |
| 2026-10-15 (in 3d) | Bolt-on acquisition close / capital-deployment update | authored | ● | 0.7 |
| 2026-10-28 (in 16d) | FOMC rate decision + press conference | macro | ●● | 0.8 |
| 2026-10-30 (in 18d) | Quarterly earnings | earnings | ●●● | 0.95 |
| 2026-12-09 (in 58d) | FOMC rate decision + SEP dot plot | macro | ●● | 0.8 |
| 2026-12-18 (in 67d) | Quarterly options-expiry cluster (3rd Friday) | opex_cluster | ● | 1.0 |
| 2027-01-27 (in 107d) | FOMC rate decision + press conference | macro | ●● | 0.8 |
| 2027-01-28 (in 108d) | FY2026 results + FY2027 organic-growth and margin guidance | authored | ● | 0.7 |
| 2027-02-15 (in 126d) | Long-range algorithm / investor update | authored | ● | 0.7 |
| 2027-03-17 (in 156d) | FOMC rate decision + SEP dot plot | macro | ●● | 0.8 |
| 2027-03-19 (in 158d) | Quarterly options-expiry cluster (3rd Friday) | opex_cluster | ● | 1.0 |
| 2027-04-28 (in 198d) | FOMC rate decision + press conference | macro | ●● | 0.8 |
| 2027-06-09 (in 240d) | FOMC rate decision + SEP dot plot | macro | ●● | 0.8 |
| 2027-06-18 (in 249d) | Quarterly options-expiry cluster (3rd Friday) | opex_cluster | ● | 1.0 |
_Sources: extended.catalysts, data/catalysts/
Regulatory & Legal Risk
| Issue | Probability | Valuation sensitivity | Horizon |
|---|---|---|---|
| FTC/state scrutiny of vitamins & supplements (VMS) health claims and 'clean'/natural labeling | medium (~30%) | low - confined to the VMS sub-portfolio, ~3-5% of FV | 12-24m |
| Ingredient/packaging and recyclability mandates raising COGS | medium (~35%) | low - margin drag absorbable via pricing, <3% of FV | 12-24m |
Probabilities and sensitivities are analyst estimates, not market-implied.
Scenario Macro & Key Risks
| Scenario | Macro assumption | Key risk |
|---|---|---|
| Structural — Private-Label / Brand Erosion | Persistent consumer trade-down and retailer private-label expansion (Walmart/Amazon own-brand push) compress branded HPC volume and pricing power together | Brand equity proves rentable rather than owned; volume AND multiple de-rate together toward private-label economics |
| Consumer / Input Recession | A consumer-spending recession with elevated commodity/logistics input costs squeezes both the top line and gross margin for 1-2 years | Pricing exhaustion; CHD cannot raise price further without ceding volume, so margin absorbs the input shock |
| Growth — Premium Innovation + EM | Successful premium innovation (VMS, specialty laundry) and international/EM expansion lift both volume and mix above the base | Innovation cadence and acquisitions fail to scale internationally where CHD lacks distribution density |
| Bull — Defensive Re-Rate | A risk-off macro regime drives a flight to defensive staples, expanding the multiple even without fundamental improvement | Re-rate is macro-driven and reverses as soon as risk appetite returns; not a durable source of value |
Scenario-macro rows withheld pending re-authoring: 1 carrying another cluster's vocabulary or a frozen figure — recorded in the narrative quarantine ledger.
Decision Rules (Machine-Checked)
Stance: Hold — 0 bullish / 0 bearish / 0 caution rules triggered of 6 evaluable (0 lacked data).
| Rule | Condition | Observed | Triggered |
|---|---|---|---|
| R1-valuation-stretch | expected return vs fair value < -12 (upside_pct) |
-1.54 | no |
| R2-valuation-opportunity | expected return vs fair value > 15 (upside_pct) |
-1.54 | no |
| R3-street-revisions | street net rating stance < -0.25 (extended.consensus.street_score) |
0.19 | no |
| R4-earnings-quality | cash conversion of earnings < 80 (extended.accounting_quality.cash_conversion_pct) |
164.9 | no |
| R5-technical-breakdown | price vs 200-day SMA < 0.85 (technicals.sma_200) |
1.02 | no |
| R6-vol-regime-shift | IV/RV vol-risk premium > 1.4 (options_overlay.iv_rv) |
1.34 | no |
Machine-checked rules over disclosed inputs. The authored falsification triggers elsewhere in this report are analyst judgment and are NOT evaluated here. The stance is what the model's own rules read on this name; it does not modify the published research rating, and it is not personal financial advice.
Reasons the Thesis Could Fail (Falsifiable)
Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:
- organic revenue growth (YoY) < 0.015 (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)
- operating margin (quarterly, non-GAAP) < 0.165 (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)
- organic volume growth (YoY) < 0.0 (2 consecutive prints). Growth that is entirely price with negative volume is the observable signature of private-label substitution — the mechanism of the structural scenario. Two consecutive negative volume prints move probability from Base to Structural.
- FY organic sales growth guidance < 0.02 (single event). (rationale withheld pending re-authoring — frozen figure or verdict)
- brand impairment or intangible write-down ($B) > 0.1 (single event). A material write-down on an acquired brand (the vitamins franchise is the precedent) is direct evidence that a category has structurally impaired, validating the brand-erosion mechanism rather than a cyclical soft patch.
Fact / Inference / Speculation
- FACT: Spot $98.11; 52-week range $81.33–$106; engine rating HOLD; house target $96.60 (-2%). (source: Alpha Vantage 2026-10-09, 12 October 2026)
- INFERENCE: Triangulated FV $81.53 (-17% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the DCF anchor sits below the multiple-discipline core.
- SPECULATION: At current prices the embedded bet is that the market keeps paying the current multiple through the capex cycle — a regime call the engine cannot verify from fundamentals alone.
Conviction Score
Research Conviction measures the strength and quality of the research setup — input coverage, financial quality, valuation support, process agreement. It is NOT the probability that the recommendation succeeds; the forecast track record section is the evidence on that.
59.1/100 (confidence band 49.4–68.7), 54th percentile of 893 covered names (as of 2026-10-10). Weighted composite under config ros-1.20.0 — every component and its inputs below.
| Component | Score (0–100) | Weight | Inputs |
|---|---|---|---|
| business quality | 67 | 15% | extended.fcf_quality.fcf_margin_pct, extended.balance_sheet.net_debt_to_ebitda, extended.accounting_quality.cash_conversion_pct |
| financial strength | 62 | 10% | extended.balance_sheet.net_debt_to_ebitda, extended.balance_sheet.interest_coverage |
| valuation | 48 | 15% | upside_pct |
| growth | 52 | 10% | reconciliation.ttm_revenue_billions, reconciliation.fy_guide_revenue_billions |
| earnings visibility | 75 | 10% | extended.forecast_accuracy.eps_surprise.beat_rate_pct |
| moat | 52 | 10% | enrichment.moat.rating |
| technical trend (heuristic — no validation record; weight change reserved for AM-060) | 61 | 10% | technicals.rsi, technicals.sma_50, technicals.sma_200 |
| macro tailwinds | — | 10% | industry_context.house |
| risk profile | 56 | 10% | monte_carlo.prob_above_current, monte_carlo.p10, monte_carlo.p90, monte_carlo.median |
Missing inputs (macro tailwinds) are excluded and the remaining weights renormalised; the confidence band widens accordingly.
Score history: 55.5 → 55.8 → 56.0 → 55.8 → 59.3 → 59.2 → 59.2 → 59.1.
Probability-Weighted Return Profile
Horizon: 1 year — at this horizon CAGR equals total return by definition. Expected values are the probability-weighted sums over the full scenario set below.
| Scenario | Probability | Target | Total return | Contribution |
|---|---|---|---|---|
| Structural — Private-Label / Brand Erosion | 20% | $44.50 | -54.6% | -10.9pp |
| Consumer / Input Recession | 18% | $80.50 | -17.9% | -3.2pp |
| Base — Pricing-Led Organic Growth | 34% | $103 | +4.9% | +1.7pp |
| Growth — Premium Innovation + EM | 20% | $129 | +31.3% | +6.3pp |
| Bull — Defensive Re-Rate | 8% | $156 | +58.6% | +4.7pp |
| Aggregate | Value |
|---|---|
| Expected return (gross, 1y) | -1.5% |
| Expected return net of SBC dilution | -3.0% |
| Outcome dispersion (σ, from MC p10–p90) | 39.0% |
| Expected Sharpe (rf 4%) | -0.14 |
| Downside expectation (prob-weighted loss branches) | -14.1% |
The gross expected return is the probability-weighted scenario return (it reconciles to the gross PWEV); the diluted figure applies the SBC share-count charge and matches the published PWEV-based target.
Expected Alpha
Expected return minus the return this name is REQUIRED to deliver for its risk (1-year horizon). Constants are pre-registered (preregistered-static (amendment #2, 2026-07-29); not fitted to MCH outcomes).
| Component | Value |
|---|---|
| Expected return (gross, 1y) | -1.5% |
| Risk-free rate | 4.49% (1y proxy (3m/2y midpoint; AV lacks a 1y tenor), as of 2026-10-08) |
| Beta (shrunk, 1y vs SPY) | 0.33 (as of 2026-10-09) |
| Equity risk premium | 4.5% |
| Required return | 6.0% |
| Expected alpha | -7.5% |
| Alpha per unit risk (EA/σ) | -0.19 |
A negative expected alpha does not change the rating — it says the expected return does not clear the risk-adjusted hurdle at today's price. Rating mechanics are unchanged by this section.
Probability Cross-Checks
Not authoritative. The scenario probabilities in this report are AUTHORED — a judgement about how the world might go, not a measurement. Nothing below modifies them, the target, the rating or any position size. These checks ask only whether anything outside our own model agrees with us; where it does not, that is information for the reader, not a correction we have quietly applied.
| Cross-check | Ours | Comparator | Reading |
|---|---|---|---|
| Scenario spread vs options market | 33.6% (1σ) | 18.9% implied | broadly consistent with the market's implied uncertainty |
| Mass above spot: scenarios vs our own MC | 62.0% | 39.9% | the scenario weights and the MC parameters disagree about our OWN view — this is a model-coherence issue, not a market disagreement |
| Realised scenario frequency | 58 dated anchors | — | 58 dated anchors available; realised-vs-prior comparison is now meaningful. |
Authored set: 5 scenarios, probabilities summing to 1.0, mean target $96.58.
Flagged for review: internal coherence (authored mass vs Monte Carlo). A flag marks a disagreement worth understanding — it does not imply either side is wrong.
Factor Exposures
Cross-sectional percentiles over 928 covered names (style scores sector-demeaned; thematic = return-beta to the theme's proxy ETF). 50 = estate median.
| Style | Percentile | Theme | Percentile | |
|---|---|---|---|---|
| Growth | 75 | AI | 8 | |
| Value | 38 | Cloud | 13 | |
| Quality | 88 | Semis | 12 | |
| Momentum | 61 | Consumer | 25 | |
| Low-Vol | 85 | Rates | 57 | |
| USD | 77 | |||
| Energy | 55 |
Market interaction: correlation vs SPY +0.02, vs QQQ -0.11 (trailing ~1y daily returns).
Rating Bridge
Rating = HOLD because:
- Probability-weighted scenario value implies -3% vs spot
- Monte Carlo median implies -10% vs spot
- DCF fair value (exit-multiple terminal) implies -22% vs spot
- Bear case (Structural — Private-Label / Brand Erosion) downside is -55% vs spot
- Net: the valuation anchor itself sits 16.9% below spot, so there is no reward leg to weigh against the bear case and the reward-to-risk ratio is withheld rather than computed off a negative upside. The rating is not asymmetric enough for a Buy and not impaired enough for a Sell — hence Hold.
Model Appendix
DCF — line items
| Year | Revenue | Op income (house path) | − Capex | + D&A | FCF | PV(FCF) |
|---|---|---|---|---|---|---|
| FY+1 | $6B | $1B | $0B | $0B | $1B | $1B |
| FY+2 | $7B | $1B | $0B | $0B | $1B | $1B |
| FY+3 | $7B | $1B | $0B | $0B | $1B | $1B |
| FY+4 | $7B | $1B | $0B | $0B | $1B | $1B |
| FY+5 | $7B | $1B | $0B | $0B | $1B | $1B |
| Terminal | — | — | — | — | $1B × 22.0x | $16B |
FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 3% of revenue, weighted from the segments) — not a single conversion fudge.
WACC 7.5% · Σ PV(FCF) $4B + PV(terminal) $16B = EV $20B; − net debt $1.9B → equity $18B ÷ diluted shares $0.24B = $76.05/share (exit-multiple terminal).
- Gordon terminal → $71.45/share — a single-point perpetual-growth cross-check at g = 2.5% (one growth rate, not a range; it is not in the blend).
- Incremental ROIC on the forecast capex ≈ 20% vs WACC 7.5% → above WACC — the build is value-creative.
Peer set
| Peer | EV/Rev | Fwd P/E | Growth | Op margin |
|---|---|---|---|---|
| CL | 3.8x | 23.6x | 4% | 21% |
| KMB | 2.5x | 14.2x | 4% | 20% |
| CLX | 2.2x | 15.1x | 4% | 17% |
| Median | 2.5x | 15.1x | — | — |
Implied prices at the peer medians: same-sub-industry median fwd P/E → $57.06; EV/Rev → $58.18.
Weighted fair-value math
| Anchor | Value | Weight | Contribution |
|---|---|---|---|
| DCF | $76.05 | 41% | $31.32 |
| Scenario PWEV | $95.16 | 29% | $27.99 |
| Monte Carlo median | $87.93 | 18% | $15.52 |
| Peer P/E | $57.06 | 12% (part weight ×1.00 — peer sits 40%–70% from the Monte-Carlo/PWEV core) | $6.71 |
| Triangulated | — | 100% | $81.53 |
Assumption Register
| Assumption | Value | Used in | Source |
|---|---|---|---|
| WACC | 7.5% | DCF discount rate | estimate (CAPM) |
| Terminal multiple | 22× | DCF exit value | house rule (0.85 × base multiple) |
| Terminal growth | 2.5% | Gordon cross-check (single point) | estimate |
| SBC dilution | 1.5%/yr | PWEV, MC, DCF (charged once) | estimate (from SBC/rev) |
| EPS basis | consensus forward EPS (broker-adjusted, non-GAAP) | all forward P/E & scenario multiples | definition |
Sensitivity-ranked drivers (widest fair-value swing first): Model op margin ±3pp (28.0); Revenue CAGR ±3pp (23.0); Terminal × ±15% (20.0); WACC ±1pp (7.0); Capex intensity ±15% (5.0).
Inputs, Sources & Confidence
Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)
| Input | Value | Type | Source | Confidence | Used in |
|---|---|---|---|---|---|
| Revenue TTM | $6.2B | reported fact | 10-K/10-Q via AV | High | Forecast base, EV/Rev |
| FY+1 guided revenue | $6.5B | company guidance | Company guidance | Medium | Forecast, SoP |
| FY+1 guided EPS | $3.7712 | company guidance | Company guidance | Medium | Forward P/E, scenarios |
| Consensus FY EPS | $3.7712 | consensus estimate | Sell-side consensus via AV | Medium | Variant perception |
| Diluted shares | 0.238B | reported fact | 10-K via AV | High | Market cap, per-share |
| Net debt / cash | $1.796B | reported fact | Balance sheet via AV | High | EV, DCF equity bridge |
| WACC | 7.5% | house estimate | CAPM (beta/rf) | Medium | DCF discount rate |
| Terminal multiple | 22× | house estimate | House rule: 0.85 × the base multiple (shared with the Monte Carlo) | Medium | DCF exit value |
| Terminal growth | 2.5% | house estimate | Long-run GDP+ | Medium | Gordon cross-check (single point, not in the blend) |
| SBC dilution | 1.5%/yr | house estimate | From SBC/revenue | Medium | PWEV, MC, DCF (charged once) |
Research Provenance
| Field | Value |
|---|---|
| Quantitative engine | mch_stock_engine v2.0 |
| Research OS config | ros-1.20.0 |
| Analysis as-of | 2026-10-12 (prices 2026-10-09) |
| Narrative authorship | claude-opus-5 · Claude Code, supervised, drafted 2026-08-16 |
| Human review | Marinus 2026-08-16 |
| Evidence | 8/8 load-bearing inputs sourced; 13/14 mandated claims cited |
| QA | scanned post-emit by the document-QA layer; the publication label (Draft / Research / Decision-level) is stamped on the published page, not authored here |
Load-Bearing Assumptions
DCF: WACC 7.5%, terminal multiple 22×, FY+5 revenue $7B. Triangulation leans 41% on DCF, 29% on PWEV, 18% on the Monte Carlo median, 12% on peer-implied value.
Appendix & audit trail — source log, data provenance, disclosures
Source Log
| Source | Type | Date | Used for | Reference |
|---|---|---|---|---|
| Alpha Vantage — GLOBAL_QUOTE / OVERVIEW | market data | 2026-10-09 | Price, market cap, EV, forward P/E | Alpha Vantage 2026-10-09 |
| MCH engine — trailing 52 weeks of daily bars | derived | 2026-10-09 | 52-week range (intraday high and low over the trailing year of the stock's own daily bars) | trailing 52 weeks of own daily bars (intraday high/low, 2025-10-10 to 2026-10-09, 251 sessions) |
| Company income statement (10-K / 10-Q) via Alpha Vantage | reported fact | 2026-10-09 | Revenue, gross/operating margin, EBIT, interest expense | INCOME_STATEMENT / latest annual |
| Company balance sheet (10-K / 10-Q) via Alpha Vantage | reported fact | 2026-10-09 | Cash, debt, net debt, leases, equity, coverage | BALANCE_SHEET / latest annual |
| Company cash-flow statement (10-K / 10-Q) via Alpha Vantage | reported fact | 2026-10-09 | Operating cash flow, capex, FCF, buybacks, dividends, SBC | CASH_FLOW / latest annual |
| Company earnings releases via Alpha Vantage | reported fact | 2026-10-09 | Reported EPS, surprise history | EARNINGS / quarterly |
| Sell-side consensus via Alpha Vantage | consensus estimate | 2026-10-09 | Forward revenue/EPS consensus, analyst count | EARNINGS_ESTIMATES |
| Earnings calendar via Alpha Vantage | market data | 2026-10-09 | Next earnings date, catalyst timing | EARNINGS_CALENDAR |
| Company guidance | company guidance | 2026-10-09 | FY guided revenue / non-GAAP EPS basis | company guidance / earnings call |
| MCH segment model (from filings & disclosures) | house estimate | 2026-10-09 | Segment revenue and multiple; model margin = gross margin − the calibrated opex ratio (not a reported margin) | company_context (authored, tagged) |
| MCH qualitative analysis | inference | 2026-10-09 | Moat, regulatory risk, scenario macro, catalysts | company_context enrichment (authored) |
| MCH investment thesis & falsification triggers | house estimate | 2026-10-09 | Thesis, anti-thesis, thesis-break signals | authored §5.3 |
Citation coverage: 13/14 mandated claims sourced. Filing URLs are not available via the market-data provider; company statements are cited as 10-K/10-Q via Alpha Vantage.
Data Sources
- Prices, fundamentals, options chain, earnings — Alpha Vantage.
- Company filings (10-K / 10-Q) — SEC filings via EDGAR.
Disclosures & Limitations
This report is for informational and research purposes only. It is not personal financial advice and does not consider any investor's objectives, financial situation, risk tolerance, tax position, or liquidity needs.
- This report is produced by the MCH Analysis quantitative research engine — valuation, scenarios, Monte Carlo and the decision layer are generated systematically from the disclosed inputs and the archetype/industry driver sets, and reviewed rather than written name-by-name. Every figure reconciles to the appendix and every score exposes its inputs.
- No suitability assessment has been performed for any individual.
- Market data may be delayed or inaccurate; figures are as of the analysis date.
- Model outputs (fair values, targets, scenario probabilities) are estimates and may be wrong.
- Forecasts are uncertain; past performance is not indicative of future returns.
- The author or publisher may hold positions in securities mentioned.
- Users should verify information against primary sources (company filings) before acting.
- Investing involves risk of loss; there is no guarantee any target price is achieved.
- Ratings follow a defined research methodology (12-month expected-return thresholds), not individual circumstances.